CC
CLDX icon

Casdin Capital’s Celldex Therapeutics CLDX Stock Holding History

Casdin Capital’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-165,000
Closed -$4.64M – 47
2022
Q3 		$4.64M Hold
165,000
– – 0.3% 28
2022
Q2 		$4.45M Buy
+165,000
New +$4.79M 0.38% 30

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Casdin Capital's CLDX Position: Q4 2022 in Review

Casdin Capital sold out of Celldex Therapeutics (CLDX) in Q4 2022, closing a stake of 165,000 shares — an estimated $4.64M sold.

Casdin Capital first reported a position in CLDX in Q2 2022 and held it in 2 quarters. The position peaked at $4.64M in Q3 2022. 168 funds tracked by Wall St. Rank hold CLDX as of Q4 2022.

  • Casdin Capital reported no remaining Celldex Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Casdin Capital sold 165,000 Celldex Therapeutics shares in Q4 2022, an estimated $4.64M.
  • Casdin Capital first reported a position in Celldex Therapeutics in Q2 2022 and held it in 2 quarters.
  • Casdin Capital's Celldex Therapeutics position peaked at $4.64M in Q3 2022.
  • 168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2022.

Based on Casdin Capital's 13F filing for Q4 2022, filed 14 Feb 2023.